by Admin | Jul 23, 2024
Synthgene Biotechnology, Areterna’s parent company, has been a leading producer of GMP-grade cap analogs, NTPs, and modified NTPs for several years, establishing a strong reputation for quality and reliability in the industry. Our raw materials play a crucial...
by Admin | Jun 5, 2024
In the intricate realm of mRNA therapeutics manufacturing, the meticulous selection of raw materials plays a pivotal role in ensuring the safety, efficacy, and ethical integrity of the final product. One crucial consideration in this process is the sourcing of animal...
by Admin | May 12, 2024
To ensure effective in vivo delivery, mRNA vaccines rely on not only optimized antigen sequences but also a robust delivery system capable of overcoming extracellular barriers, facilitating endosomal escape, and evading intracellular immune responses. Lipid...
by Admin | Apr 25, 2024
In recent years, mRNA vaccines and drugs have received widespread attention around the world. Areterna LLC is proud to introduce Fluc-eGFP mRNA (Catalog number: 11013-CAP), a cutting-edge tool to accelerate your mRNA research. This mRNA encodes both eGFP and...
by Admin | Apr 17, 2024
In vitro transcription (IVT) remains the predominant method for large-scale mRNA synthesis due to its efficiency and scalability. However, a significant challenge associated with IVT is the residual double-stranded RNA (dsRNA) produced as a by-product. This dsRNA can...
by Admin | Mar 25, 2024
In-vitro transcription (IVT) is a reactor-based scheme to manufacture RNA where cell-derived impurities or adventitious contaminants can be avoided thus making the manufacturing process GMP-friendly. The IVT reaction is often carried out at 37°C for 2...
